MediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA Status
Portfolio Pulse from Vuk Zdinjak
MediPharm Labs Corp. has made its first delivery of cannabis clinical trial materials to the US for use in an NIH funded clinical trial. The company has also completed the US FDA drug API manufacturer inspection at its Ontario facility. MediPharm is now a registered foreign drug manufacturing site with the US FDA and believes it is the only Canadian Pharmaceutical company with this registration. This allows MediPharm to further market cannabidiol API to pharmaceutical companies for new novel drugs, generic drugs, and clinical trial materials.
August 01, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediPharm's successful delivery and FDA inspection could open up new commercial opportunities for the company.
The successful delivery and FDA inspection completion are significant milestones for MediPharm, potentially opening up new commercial opportunities. This could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
As MediPharm's successful delivery and FDA inspection could open up new commercial opportunities, this could positively impact its stock.
The successful delivery and FDA inspection completion are significant milestones for MediPharm, potentially opening up new commercial opportunities. This could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100